VSTM: Major data update for G12D inhibitor set for October, with phase III trials and partnerships ahead
Significant clinical progress was highlighted for the G12D inhibitor, with major data updates expected in October and phase III trials planned for next year. The drug is positioned as best-in-class, with strong efficacy, safety, and combinability, while commercial growth continues in ovarian cancer…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.